UK scientists are developing a vaccine for the Bundibugyo strain of Ebola, with trials potentially ready within months, as an outbreak in the Democratic Republic of Congo (DRC) continues to spread.
The Bundibugyo strain, a rare species of Ebola, kills approximately one-third of those infected and currently has no proven vaccine. This particular strain has not had a vaccine available for use, unlike other Ebola strains that have received more development attention.
The Oxford Vaccine Group is leading the development of the new vaccine. The vaccine utilizes the same technology that was used in the AstraZeneca Covid-19 vaccine, applying established platform technology to address the Bundibugyo strain.
The Ebola outbreak in the DRC is "spreading rapidly," according to the director-general of the World Health Organisation (WHO). The WHO is monitoring the situation as scientists work to develop a vaccine that could address this specific strain.
The Bundibugyo strain presents particular challenges for public health officials. As a rare species of Ebola, it has not received the same level of vaccine development attention as other strains. The mortality rate of approximately one-third of those infected makes it a health concern in affected regions where outbreaks occur.
The Oxford Vaccine Group's approach applies established vaccine technology to this new challenge. The same platform technology used to develop the AstraZeneca Covid-19 vaccine is being used to create a vaccine candidate for Bundibugyo Ebola. This approach leverages existing research and development infrastructure to address the current outbreak.
According to sources, the vaccine could be ready for trials in months. The development timeline represents an effort to address the current outbreak in the DRC, where the WHO has indicated the situation is evolving.
The WHO director-general's statement that the outbreak is "spreading rapidly" indicates the urgency of the situation. Health authorities are working to contain the outbreak while vaccine development proceeds.
The Oxford Vaccine Group's work on the Bundibugyo vaccine is part of ongoing efforts to develop medical countermeasures for Ebola. The lack of a proven vaccine for this strain has been identified as a gap in health preparedness.
As development continues, scientists are working toward beginning trials. The WHO continues to track the outbreak in the DRC, and health officials are coordinating response efforts to address the spread of the virus.
Read the original coverage
💬 Comments
📜 Comment Policy